Abstract
Tumor biology is intricate and multifaceted. The genetic and epigenetic alterations accelerate normal cells to transform into aggressive malignant phenotype. Molecular principles of invasion and metastasis are indeed indispensable for profound understanding of tumorigenesis. The seeding pioneer cells from growing tumor eventually discharge from the original clump of mutant cells, invading adjacent tissues and mobilizing to distant sites. This attribute of cancer cells reduces patient’s survival rate and prognosis. Inquisition of mechanistic approach for metastasis is bestowed by two processes—extracellular matrix (ECM) remodeling and epithelial-mesenchymal transition (EMT). Proteases pave the way for invaders by breaking down the ECM and releasing pro-invasive factors from cell surface and ECM. Indeed, highly conserved EMT program leads to dissemination of single tumor cells from primary tumors. The zinc-dependent matrix MMPs are the most important effectors in these processes and frequently overexpressed in most of the tumors. Besides proteolysis, by activating or deactivating several growth factors, MMPs affect tumor neoangiogenesis and proliferation. The tissue inhibitors of metalloproteinases (TIMPs) play a central role in complex regulation of MMPs. An apt equilibrium between TIMPs and MMPs is significant in cell invasion and metastasis. These concepts are encouraged for pursuing MMPs as a signature for predicting metastasis and also as therapeutic target. A comprehensive understanding regarding enzyme-substrate interactions and regulation and specific MMPs’ functionality in cancer addresses that MMP inhibitors (MMPIs) should be specific in terms of MMP or degrading definite substrates. The scientific and clinical drive for second-generation MMPIs through the development of pharmaceutical reagents and clinical trials determining the therapeutic benefit to cancer patients should be geared up.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Leber MF, Efferth T (2009) Molecular principles of cancer invasion and metastasis. Int J Oncol 34:881–895
Hahn WC, Weinberg RA (2002) Rules for making human tumor cell. N Engl J Med 347:1593–1603
Veiseh O, Kievit FM, Ellenbogen RG, Zhang M (2011) Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev 63(8):582–596
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093–1102
Friedl P, Gilmour D (2009) Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10:445–457
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61
Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222–243
Tammela T, Alitalo K (2010) Lymphangiogenesis: molecular mechanisms and future promise, cell 140 (2010) 460–476. Cell 140:460–476
Alitalo K, Tammela T, TVP P (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953
Martin TA, Ye L, Sanders AJ, Lane J, Jiang WG (2000) Cancer invasion and Metastasis: molecular and cellular perspective. Madame Curie Biosci Database:1–34
Yilmaz M, Christofori G, Lehembre F (2007) Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 13(12):535–541
Van Zijl F, Krupitza G, Mikulits W (2011) Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res Rev Mutat Res 728(1–2):23–34
Sabeh F, Shimizu-Hirota R, Weiss SJ (2009) Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 185:11–19
Christofori G (2006) New signals from the invasive front. Nature 441:444–450
Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454
Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22:7155–7169
Massague J (2008) TGFbeta in cancer. Cell 134:215–230
Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548–558
Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T (2004) NF-kappaB is essential for epithelial–mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569–581
Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta Rev Cancer 1796(2):293–308
Debois JM (2002) TXNXM1: the anatomy and clinics of metastatic cancer. Kluwer Academic Publisher, Dordrecht
Schouten LJ, Rutten J, Huveneers HA TA (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 95:2698–2705
GR M (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593
Martin TA, Ye L, Sanders A et al (2000) Cancer invasion and metastasis: molecular and cellular perspective. 1–7
Birchmeier W BJ (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198:11–26
Trusolino L, Bertotti ACP (2001) A signalling adapter function for alpha6β4 integrin in the control of HGF-dependent invasive growth. Cell 107:643–654
Mareel M LA (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–376
Arakaki PA, Marques MR, MCS (2009) MMP-1 polymorphism and its relationship to pathological processes. J Biosci 34(2):313–320
Alberts B (2008) Molecular biology of the cell, 5th edn. Garland Science, New York
Friedlander DR et al (1994) The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J Cell Biol 125(3):669–680
Trowbridge JM, RLG (2002) Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 12(9):117R–125R
Bassols A, JM (1988) Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J Biol Chem 263(6):3039–3045
Hacker U, Nybakken K, NP (2005) Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 6(7):530–541
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395–406
Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3(12):1–24
Pickup MW, Mouw JK, Weaver VM (2014) The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 15(12):1243–1253
Gupta GP, Massagu J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695
Kalluri R, Weinberg RA (2009) Review series the basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Yang J, Weinberg R (2008) Epithelial mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829
Jechlinger M, Grunert S, Beug H (2002) Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. J Mammary Gland Biol Neoplasia 7:415–432
Zeisberg M et al (2003) BMP-7 counteracts TGFbeta1- induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968
Kim K, Lu Z, Hay ED (2002) Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 26:463–476
Eger A, Stockinger A, Schaffhauser B, Beug HA, Foisner R (2000) Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 148:173–188
Bhowmick NA et al (2001) Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12(12):27–36
Bhowmick NA, Zent R, Ghiassi MM, M, Moses HL (2001) Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 276:46707–46713
Watanabe T et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206
Neil JR, Johnson KM, Nemenoff RA, Schiemann WP (2008) Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 29:2227–2235
Tepass U, Truong K, Godt D, Ikura MA, Peifer M (2000) Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol 1:91–100
Muta H et al (1996) E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res 87:843–848
Medici D, Hay ED, Olsen BR (2008) Snail and slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factorbeta3. Mol Biol Cell 19:4875–4887
Blanco MJ et al (2002) Correlation of snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21:3241–3246
Yokoyama K et al (2001) Reverse correlation of Ecadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol 37:65–71
Radisky DC et al (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127
Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910–14914
Gregory PA et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601
Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894–907
Zavadil J, Narasimhan M, Blumenberg MA, Schneider RJ (2007) Transforming growth factorbeta and microRNA: mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 185:157–161
Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890
Weinberg RA (2006) The biology of cancer. Garland Science, New York
Van Lint PLC (2007) Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 82:1375–1381
Brew KNH (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803:55–71
Johnson LL, Dyer RHD (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2:466–471
Massova I, Kotra LP, Fridman RMS (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12:1075–1095
Sternlicht MDWZ (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516
Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R et al (2001) MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 263:209–223
Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J et al (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 98:12485–12490
DR E (2001) Matrix metalloproteinase inhibitors in cancer therapy. In: Clende. Humana Press, Totowa
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG Q V (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (80–)277:225–228
Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M et al (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069–1079
Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P et al (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272:25706–25712
Whitelock JM, Murdoch AD, Iozzo RVUP (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271:10079–10086
Yu QSI (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163–176
Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118
Kajita M, Itoh Y, Chiba T, Mori HOA (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153:893–904
Hadler-Olsen E, Winberg JO, Uhlin-Hansen L (2013) Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol 34(4):2041–2051
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer–trials and tribulations. Science 295(80):2387–2392
Anfinsen CB Christian B (1995) Adv Prot Chem 47. (Academic Press)
Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573
Davies B, Mi1es DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR (1993) Activity of type IV collagenases in benign and malignant breast disease. Brit J Cancer 67:1126–1131
Davies B, Waxman J, Wasan H et al (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365–5369
Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases I and 3, tissue inhibitor of metalloproteinase-l and the comp1ex of metalloproteinase- I tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74:220–223
Halaka A, Bunning R, Bird C, Gibson M, Reynolds J (1983) Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. J Neurosurg 59:444–461
Boudreau N, Sympson C, Werb Z, Bissell M (1995) Suppression ofiCE and apoptosis in mammary epithelial cells by extracellular matrix. Seience 267:891–893
Alexander CM, Howard E w, BisselI MJ, Werb Z (1996) Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase- l transgene. J Cell Biol 135:1667–1677
Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rosejohn S, Massagué J (1996) Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271:11376–11382
Levi E, Fridman R, Miao H, Ma Y, Yayon A, Vlodavsky I et al (1996) Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor. Proc Natl Acad Sci U S A 93:7069–7074
Suzuki M, Raab G, Moses M, Femandez C, Klagsbrun M (1997) Matrix metalloproteinase- 3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Bio Chem 272:31730–31737
Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JDAH et al (1994) Processing of tumour necrosis factor-a precursor by metalloproteinases. Nature 370:555–557
Thrailkill KM, QuarIes LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL (1995) Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136:3527–3533
Rajah R, Nunn SE, Herrick DJ, Grunstein MM, Cohen P (1996) Leukotriene d-4 induces MMP-l, which functions as an IGFBP protease in human airway smooth muscle cells. Am J Phys 15:1014–L1022
Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metast Rev 9:203–226
Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y (1997) Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-betal release. Biochem J 322:809–814
Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626
StCroix B, Sheehan C, Rak J, Florenes V, Slingerland J, Kerbel R (1998) E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27Kip1. J Cell Biol 142:557–571
Mareei M, Kint J, Meyvisch C (1979) Methods of study of the invasion of malignant C3H mouse fibroblasts into embryonic chick heart in vitro. Virchows Arch B 30:95–111
Thorgeirsson U, Liotta L, Kalebic T, Margulies I, Thomas K, Rios-Candelore ME et al (1982) Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. J Natl Cancer Inst 69:1049–1054
Repesh L (1989) A new in vitro assay for quantitating tumor ceH invasion. Invas Metast 9:192–208
Hendrix M, Seftor E, Seftor R, Fidler I (1987) A simple quantitative assay for studying the invasive potential of high and low metastatic variants. Cancer Lett 38:137–147
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67–68
Schultz, R., Silberman, S., Persky, B., Bajkowski, A., and Carmichael D (1988) Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine BI6-FlO melanoma cells. Cancer Res 48:5539–5545
Powell W c, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB et al (1993) Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417–422
Deryugina E, Luo G, Reisfeld R, Bourdon M, Strongin A (1997) Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17:3201–3210
Gomez D, Alonso D, Yoshiji H, Thorgeirsson U (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological function. Eur J Cell Biol 74:111–122
Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro AB, PD et al (1994) Inhibition of the metastatic spread and growth of BI6-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464
Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087–2091
An ZL, Wang XE, Willmott N, Chander SK, Tickle S, Docherty AJP et al (1997) Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastas 15:184–195
Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464
Lin CY et al (2011) Matrix metalloproteinase-9 cooperates with transcription factor snail to induce epithelial-mesenchymal transition. Cancer Sci 102(4):815–827
Gavrilovic J, Moens GTJ et al (1990) Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regul 1(13):1003–1014
Gilles C, Polette MCC et al (2001) Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci 114(16):2967–2976
Buisson AC, Zahm JMPM et al (1996) Gelatinase B is involved in the in vitro wound repair of human respiratory epithelium. J Cell Physiol 166(2):413–426
Legrand C, Gilles CZJ et al (1999) Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol 146(2):517–529
Daja MM, Niu XZZ et al (2003) Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis 6(1):15–26
Gilles C, Polette MPJ et al (1994) Epithelial-to-mesenchymal transition in HPV-33-transfected cervical keratinocytes is associated with increased invasiveness and expression of gelatinase A. Int J Cancer 59(5):661–666
Yokoyama K, Kamata NFR et al (2003) Increased invasion and matrix metalloproteinase-2 expression by Snailinduced mesenchymal transition in squamous cell carcinomas. Int J Oncol 22(4):891–898
Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJIT (2007) Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97(7):971–977
Wilson S, Wakelam MJ, Hobbs RF, Ryan AV, Dunn JA R, VD et al. (2006) Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. BMC Cancer 6(258)
Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash FE-Z, TM. (2007) Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 52(5):1388–1396
Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM L, CC et al (2008) Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 14(20):6610–6617
Cribier B, Noacco G, Peltre BGE (2002) Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 46(3):408–413
Kim HJ, Lee JY, Kim SH, Seo YJ, Lee JH, Park JK et al (2007) Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 157(2):319–324
Morrison CJ, Butler GS, Rodriguez DOC (2009) Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 21(5):645–653
Terp GE, Cruciani G, Christensen ITJF (2002) Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J Med Chem 45(13):2675–2684
Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D M, M et al. (2005) Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87(3–4):393–402.
Chung L, Shimokawa K, Dinakarpandian D, Grams F FG, H N (2000) Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem 275(38):29610–29617
Chung L, Dinakarpandian D, Yoshida N, Lauer-Fields JL F, GB Visse R et al (2004) Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 23(15):3020–3030
Manka SW, Carafoli F, Visse R, Bihan D, Raynal N F, RW et al (2012) Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A 109(31):12461–12466
Kousidou OC, Mitropoulou TN, Roussidis AEKD, Theocharis ADKN (2005) Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 26(4):1101–1109
Mitropoulou TN, Tzanakakis GN, Kletsas D KH, NK K (2003) Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer J Int du Cancer 104(2):155–160
Hua J MR (1996) Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56:5279–5284 56:5279–5284
Yonemura Y, Endo Y, Fujita H, Kimura K, Sugiyama K et al (2001) Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J Exp Clin Cancer Res 20:205–212
Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL et al. (2000) Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60:6851–6855, 60:6851–6868
Elkin M, Reich R, Nagler A, Aingorn E, Pines M et al (1999) Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 5:1982–1988, 5:1982–1988
Silletti S, Kessler T, Goldberg J, Boger DL C DA (2001) Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A 98:119–124
Liu S, Netzel-Arnett S, Birkedal-Hansen HLS (2000) Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 60:6061–6067
Hidalgo MES (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP et al (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774
Falardeau P, Champagne P, Poyet P, Hariton C DE (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28:620–625
Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R et al (1999) Tumor invasion: molecular shears blunted by green tea. Nat Med 5:1216
Jiang MC, Liao CFLP (2001) Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 282:671–677
Ala-aho R, Johansson N, Grénman R, Fusenig NE, López-Otín C et al (2000) Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene 19:248–257
Ma Z, Qin HBE (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol 167:5150–5159
Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ et al (2001) Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7:2840–2853
Mengshol JA, Mix KSBC (2002) Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark? Arthritis Rheum 46:13–20
Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE et al (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335–3339
Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM et al (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551–1559
McGaha TL, Phelps RG, Spiera HBC (2002) Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming growth- factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118:461–470
Simon C, Goepfert HBD (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 58:1135–1139
Johansson N, Ala-aho R, Uitto V, Grénman R, Fusenig NE et al (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113:227–235
Futamura M, Kamiya S, Tsukamoto M, Hirano A, Monden Y et al (2001) Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 20:6724–6730
Zhang Y, Thant AA, Machida K, Ichigotani Y, Naito Y et al (2002) Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 62:3962–3965
Karin MCL (2001) AP-1--glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 169:447–451
Al. ST et al (2002) Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix meta. Cancer Res 62:1025–1029
Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ et al (2000) Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 275:10405–10412
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(59):2615–2622
Ala-aho R, Grénman R, Seth PKV (2002) Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 21:1187–1195
Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D et al (2002) Green tea polyphenol (−)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta 1542:209–220
Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G et al (2001) Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A 98:10326–10331
Khatib AM, Siegfried G, Chrétien M, Metrakos PSN (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160:1921–1935
Huang X, Chen S, Xu L, Liu Y, Deb DK et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478
Wang S, Cheng Y, Wang F, Sun L, Liu C et al (2008) Inhibition activity of sulfated polysaccharide of Sepiella maindroni ink on matrix metalloproteinase (MMP)-2. Biomed Pharmacother 62:297–302
Berton A, Rigot V, Huet E, Decarme M, Eeckhout Y et al (2001) Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases a and B by long-chain unsaturated fatty acids. J Biol Chem 276:20458–20465
Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL et al (2007) The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio. BMC Evol Biol 7:63
Fujita M, Nakao Y, Matsunaga S, Seiki M, Itoh Y et al (2003) Ageladine a: an antiangiogenic matrix metalloproteinase inhibitor from the marine sponge Agelas Nakamurai. J Am Chem Soc 125:15700–15701
Lelièvre Y, Bouboutou R, Boiziau JCT (1989) Inhibition of synovial collagenase by actinonin. Study of structure/activity relationship. Pathol Biol 37:43–46
Acknowledgments
We gratefully acknowledge the Department of Science and Technology (DST)—INSPIRE—India.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Rajesh, Y., Mandal, M. (2017). Regulation of Extracellular Matrix Remodeling and Epithelial-Mesenchymal Transition by Matrix Metalloproteinases: Decisive Candidates in Tumor Progression. In: Chakraborti, S., Dhalla, N. (eds) Proteases in Physiology and Pathology. Springer, Singapore. https://doi.org/10.1007/978-981-10-2513-6_9
Download citation
DOI: https://doi.org/10.1007/978-981-10-2513-6_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2512-9
Online ISBN: 978-981-10-2513-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)